Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study
| Autor: | M Tejada, G Pizzarelli, Sonia Senesi, Federico Marchetti, Mario Campa, P. Favini, Tecla Malizia |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Microbiology (medical)
Peptic Ulcer medicine.drug_class Lansoprazole Microbial Sensitivity Tests Azithromycin Pharmacology Flurithromycin 2-Pyridinylmethylsulfinylbenzimidazoles Helicobacter Infections Macrolide Antibiotics Organometallic Compounds Humans Medicine Pharmacology (medical) Omeprazole Antibacterial agent Roxithromycin Helicobacter pylori biology business.industry Drug Synergism Proton Pump Inhibitors Anti-Ulcer Agents bacterial infections and mycoses biology.organism_classification Anti-Bacterial Agents Erythromycin Infectious Diseases Bismuth Subcitrate Gastric Mucosa Gastritis business medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 41:29-35 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/41.suppl_2.29 |
| Popis: | Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed. Chequerboard titration was used to analyse the results of antimicrobial interactions and showed that the activity of macrolides was enhanced by combining them with lansoprazole, omeprazole or, to a lesser extent, bismuth subcitrate. While the interactions between erythromycin and the proton-pump inhibitors or bismuth subcitrate were always additive, the combinations of roxithromycin-lansoprazole, flurithromycin-omeprazole and azithromycin-lansoprazole acted synergically on 82%, 60% and 60% of H. pylori strains, respectively. These results may, in part, account for the enhanced clinical efficacy of macrolides administered with proton-pump inhibitors in the treatment of H. pylori-associated diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|